Potential Collaboration for GSK’s RSV Vaccine The amended deal also includes exclusive rights for China's largest vaccine company to explore collaboration on GSK's RSV vaccine Arexvy in China ...
Under the revised agreement, GSK will collaborate exclusively with Zhifei on the commercialization of its respiratory syncytial virus vaccine Arexvy in China for an initial period of 10 years ...
GSK said Zhifei also has agreed to exclusively engage in discussions of a potential collaboration on the commercialisation of its respiratory syncytial virus vaccine, Arexvy, subject to regulatory ...
There was a slightly worse-than-expected performance for respiratory syncytial virus (RSV) vaccine Arexvy and a decline in sales for GSK's important vaccines business. While outside the usual RSV ...
The suits allege that nanoparticles used in Moderna's Spikevax COVID-19 shot and recently approved mResvia vaccine for RSV – which competes with GSK's $1.7 billion blockbuster Arexvy ...
GSK tries to steady the ship as Arexvy sales plummet in wake of CDC guidance changes When GSK penned the Zhifei pact last year, the companies said there’s a possibility to potentially expand the ...
The FDA has approved three vaccines to prevent RSV in adults who are 60 and older: Moderna’s mRESVIA, approved in June 2024, and GSK’s Arexvy and Pfizer’s Abrysvo, both approved in May 2023. The ...
GSK said Zhifei also has agreed to exclusively engage in discussions of a potential collaboration on the commercialisation of its respiratory syncytial virus vaccine, Arexvy, subject to regulatory ...
GSK has global clinical development programmes underway to evaluate the safety and immunogenicity of Arexvy in adults aged 18+ at increased risk of RSV disease. The GSK proprietary AS01 adjuvant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback